NanoViricides, Inc.

1.8600+0.33 (+21.6%)

Oct 29, 4:00:00 PM EDT · NYSE American · NNVC · USD

Upcoming Earnings

Report date

Key Stats

Market Cap

32.42M

P/E (TTM)

Basic EPS (TTM)

-0.63

Dividend Yield

Recent Filings

10-K

FY2025 results

9/29/25Sep 29, 2025

NanoViricides ended FY2025 with no revenues and a net loss of $9.5 million, up from $8.3 million last year, driven by higher R&D on NV-387 and investor outreach costs, while cash dipped to $1.6 million amid ongoing clinical pushes. The standout momentum came from NV-387, the broad-spectrum antiviral that aced Phase Ia/Ib safety trials with zero adverse events in healthy volunteers, paving the way for dual Phase II trials: one targeting MPox in the Democratic Republic of Congo, where preliminary ethics approval signals Q4 acceleration versus Q3 planning, and another innovative basket trial for viral acute respiratory infections (ARI/SARI) to test efficacy across Influenza, RSV, and Coronaviruses without virus-specific delays. Q4 saw sequential gains in manufacturing scale-up, doubling NV-387 batch sizes to 6kg for smoother trial supply, while animal models confirmed superior lung protection over approved Influenza drugs, hinting at margin-like efficiency in broad-spectrum action. Liquidity remains tight with $3 million credit access, but no capex shifts or dividends; the year closed eyeing non-dilutive biodefense grants for Smallpox under FDA's Animal Rule. Yet regulatory hurdles in emerging markets could stall quarterly momentum.

10-Q

Q3 FY2025 results

5/15/25May 15, 2025

NanoViricides posted a Q3 net loss of $2.2M, up 20% y/y, with operating expenses climbing to $2.2M from $1.9M amid higher R&D and investor outreach costs. For the nine months, the net loss widened to $7.4M from $5.9M, driven by $4.4M in R&D and $3.1M in G&A, while cash burned $6.8M in operations versus $4.8M last year. Equity raises netted $4.6M, leaving $2.5M in cash against $1.2M liabilities, but liquidity strains persist with no revenue and ongoing Phase II prep for NV-387 in MPox and RSV trials. No debt drawn from the $3M related-party line maturing March 2026. Cash won't last 12 months without fresh funding.

10-Q

Q2 FY2025 results

2/14/25Feb 14, 2025

NanoViricides narrowed its Q2 operating loss to $2.1M from $2.2M a year earlier, while YTD operating loss widened to $5.2M from $4.2M, driven by higher general and administrative costs tied to investor outreach. No revenue yet, but R&D spend held steady at $3.1M YTD, supporting Phase I completion of broad-spectrum antiviral NV-387 with zero adverse events. Cash dipped to $4.0M from $4.8M at fiscal year-end, offset by $4.0M from equity sales; free cash flow not disclosed in the 10-Q. The $3M related-party line of credit remains undrawn through March 2026. NV-387 advances to Phase II trials for MPox and RSV, building on strong animal data. Yet regulatory hurdles in funding-strapped biotech demand careful navigation.

8-K

Annual meeting approves board, auditors

12/12/24Dec 12, 2024

NanoViricides held its 2024 annual stockholder meeting on December 7, with 47.1% of voting shares present. Shareholders re-elected Theodore Rokita as Class I director and Makarand Jawadekar and Brian Zucker as Class II directors for two-year terms, while ratifying EisnerAmper LLP as auditors for the fiscal year ending June 30, 2025. Directors won handily despite some opposition. The vote signals steady governance continuity.

10-Q

Q1 FY2025 results

11/14/24Nov 14, 2024

NanoViricides posted a Q1 FY2025 net loss of $3.1M, up 59% y/y from $2.0M, driven by higher R&D costs for NV-387 Phase II preparations and G&A from investor outreach, while operating cash burn hit $2.6M versus $1.2M last year. No revenue yet, but cash stood at $3.9M with $1.7M raised via ATM equity sales; free cash flow not disclosed in the 10-Q. The team advanced NV-387, a broad-spectrum antiviral, toward RSV and MPox trials after a clean Phase I safety run, with a new TheraCour MoU securing ROFR on future antivirals. Liquidity remains tight, flagged as a going concern risk. Yet regulatory hurdles loom large.

About

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

CEO

Dr. Anil R. Diwan Ph.D.

IPO

10/26/2005

Website

https://www.nanoviricides.com

Employees

Sector

Healthcare

Industry

Biotechnology